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Winstone Zulu is featured prominently in a tuberculosis (TB) and HIV awareness 
campaign sponsored by the Stop TB Partnership, a network of organizations, countries 
and donors that have made the elimination of tuberculosis a priority. He is a Zambian 
who contracted HIV and later acquired infection with TB. He managed to survive the co-
infection when so many around him, including four of his brothers, died of tuberculosis 
in the 1990s. This defining experience led him to become a leading advocate for TB and 
HIV patients worldwide. Like those in his family, many people in sub-Saharan Africa 
and throughout the world who suffer from TB and HIV do not survive the deadly 
combination. The terrifying consequences of the two infections have now become even 
graver- a newer threat of multi-drug resistant TB (MDR-TB) jeopardizes what little 
control there is now over the dual epidemic. Understanding the relationship between 
HIV and MDR-TB has profound implications for the many people like Winstone Zulu's 
brothers, who have all but received a death sentence. 
The Scope ofTB 
Tuberculosis has long been a cause of human suffering and death. This trend has 
continued into the modem day; in 2005, there were about 8.8 million incident cases of 
TB worldwide and over 14 million prevalent cases. In the same year, about 1.6 million 
people died from tuberculosis. 1 Not surprisingly, the global distribution of the burden of 
suffering is skewed. South-East Asia, which includes India, had the most incident cases 
in 2005 with about 3 million cases of TB, accounting for about 34% of disease incidence. 
The highest incident rates ofTB occur in Africa, with a rate of343 per I 00,000 compared 
to 181 in South-East Asia and 39 in the Americas. The highest mortality rates also occur 
in Africa (74 per 100,000).1 While TB remains a major cause of mortality, incidence 
rates have recently remained stable or have declined in most regions worldwide. 
Nonetheless, the number of new TB cases still rose slightly in 2005 because of the case 
load in Africa and South-East Asia.2 
Though tuberculosis has consistently remained a major cause of morbidity and 
mortality worldwide, it has received varying levels of attention from the public health and 
medical community. Initial large scale public health responses to tuberculosis began in 
the post World War II era as vertical programs. This approach succeeded in stemming 
the tide of infection in industrialized countries but did little to control TB in resource 
poor countries.3 In the latter, TB control had to be incorporated into the general health 
services. This integration into general health services marginalized tuberculosis control 
efforts in certain nations for decades. This continued into the 1980s as the HIV pandemic 
was about to profoundly increase rates of tuberculosis worldwide. 
In the early 1990s, rising rates of tuberculosis and particularly MDR-TB in 
developed countries began to get publicity. In the United States, outbreaks of TB and 
MDR-TB in New York City and Miami were traced initially to HIV infection but were 
also noted in immigrant communities.4 The high fatality rates of these outbreaks led to 
calls for better tuberculosis control in the United States. At the same time, TB rates in 
certain African countries, such as Tanzania, Malawi and Zimbabwe, rose rapidly, leading 
to calls for a thorough rethinking of tuberculosis control efforts worldwide. 5 
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Response to the resurgence and drug resistance 
In 1995, the World Health Organization adopted the DOTS (Directly Observed 
Therapy Short-Course) program as a systematic strategy to combat rising rates ofTB. 
Among the central tenets ofthe program was the recognition ofTB chemotherapy as a 
highly cost effective intervention. Also important were government commitment to TB 
.control, diagnosis with sputum microscopy, appropriately managed short-course 
chemotherapy, readily available pharmaceuticals and infrastructure for outcomes 
measurement.4 Initial efforts in the DOTS era proved limited as only 11% ofTB cases 
were estimated to be treated under its guidelines in a 1997 study.6 DOTS gradually 
expanded but its shortcomings led to new threats: the double threat of HIV /TB and the 
continued escalation ofMDR-TB rates. 
MDR-TB is defined as mycobacterium tuberculosis that is resistant to both 
isoniazid and rifampin (or rifampicin). For an accurate diagnosis ofMDR-TB, both 
sputum cultures of the organism as well as drug sensitivities are necessary. Selection for 
drug resistant strains of tuberculosis generally arises from a combination of medical error 
(health care worker or infrastructure level) and poor patient adherence to the complicated 
drug regimen. Because inadequate treatment selects for resistant strains, re-treatment 
cases ofTB have higher rates ofMDR-TB (and all drug resistance patterns) as compared 
to new cases7 In fact, previous drug treatment is the most important risk factor for 
MDR-TB.8 These resistant strains become problematic because patients acquire longer 
periods of infectiousness and the treatment regimens can last up to 24 months. These 
changes are due to the fact that isoniazid is the most potent bactericidal drug of the four 
drug regimen of short-course chemotherapy while rifampin is the best sterilizing drug. 
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However, the most important consequence of resistance is that MDR-TB has higher 
treatment failure and death rates in new andre-treatment cases.9 Aside from the 
pharmacologic and physiologic properties, MDR-TB treatment is prohibitively more 
expensive than the traditional six month short-course chemotherapy. Accordingly, the 
financial burden ofMDR-TB places considerable stress on the health budgets of resource 
poor nations. 
Investigations into the prevalence and trends ofMDR-TB began with the 
WHO/IUALTD Global Project on Anti-tuberculosis Drug Resistance Surveillance, which 
was completed in 1997 .10• 11 These reports demonstrated that drug resistant TB, including 
MDR-TB, was present worldwide and that better TB control practices were associated 
with lower rates of bacterial resistance. Furthermore, MDR-TB was shown to be 
especially problematic in certain 'hot-spots' such as Russia, Latvia and the Dominican 
Republic. A follow up report from 2001 showed especially high rates ofMDR-TB in 
certain areas? While the median rate ofMDR was 1.0% among new cases ofTB, the 
rates varied considerably. MDR accounted for 14.1% of new cases in Estonia, 9.0% of 
new cases in Latvia, 9.0% of new cases in the Ivanovo oblast (region) of Russia, 5.0% of 
new cases in Iran and 4.5% of cases in the Zhejiang province of China. The latest report 
from WHO/IUALTD confirms these "hot spots" of epidemic MDR-TB while 
additionally warning about high rates ofMDR-TB in Kazakhstan, Lithuania, Uzbekistan, 
Ecuador and Israel. 12 
The surging rates ofMDR-TB, especially in the "hot spots" led to renewed debate 
over TB control policy. Implicit in the debate was value of allocating a tremendous 
amount of resources on the difficult problem ofMDR-TB. One proposal was a 
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complementary DOTS-plus program, which would uses DOTS programs as a base to 
address MDR-TB in needed areasY Patients with drug resistant TB would be treated on 
individualized regimens. At the same time, others contended that the best use of 
resources was to focus on treating drug susceptible TB with short course chemotherapy .14 
Not only would this strategy be cheaper, but effective control of susceptible TB leads to 
effective prevention ofMDR-TB. 
With the rethinking of the DOTS strategy and disappointments in MDR-TB and 
TB/HIV control, a new Stop TB Strategy came to fruition in early 2006. The underlying 
reason for the Stop TB Strategy was that DOTS alone would be inadequate for achieving 
the 2015 Millennium Development Goals related to TB, which include halting and 
reversing the incidence of tuberculosis by 2015. 15• 16 The Stop TB Strategy includes 
expansion of DOTS but also addresses other issues. It promotes collaboration between 
TB/HIV control efforts and prevention and control ofMDR-TB. Other components 
include structural changes as a method of curbing TB. These consist of strengthening 
health systems, engaging health care providers, empowering TB patients and their 
communities, and promoting TB research regarding diagnostics, drugs and vaccines. The 
heightened emphasis on HIV and MDR-TB will hopefully lead to a better understanding 
of the relationship between HIV, TB and drug resistance as well as decrease the case load 
ofTB/HIV co-infection and drug resistant TB. 
Co-infection with TB and HIV 
One of the greatest current challenges facing TB control is HIV control. HIV 
(human immunodeficiency virus) is a retrovirus which causes immune deficiency and 
5 
leads to the clinical syndrome AIDS. Currently, there are an estimated 39.5 million 
people living with HIV around the world. Around 4.3 million new people were infected 
with the virus in 2006 and about 2.9 million died of AIDS.17 The burden of suffering is 
concentrated in sub-Saharan Africa, which contains 63% of cases. HIV prevalence 
worldwide continues to increase; an estimated 2.6 million more people had HIV in 2006 
compared to two years previously. The most conspicuous increases have been in Eastern 
Europe and Central Asia, two areas also hard hit by the TB epidemic. 17 
HIV changes the epidemiology, case presentation and pathophysiology of 
tuberculosis infection. The virus increases the chances of a reactivation of latent TB 
infection in addition to speeding the progression of active TB disease. TB patients with. 
HIV are more likely to have atypical signs and symptoms of the disease and more likely 
to have extrapulmonary dissemination. The pharmacologic treatment of TB is 
particularly difficult in HIV patients because of the interactions between protease 
inhibitors and rifampin. Furthermore, treatment ofHIV can paradoxically worsen TB 
disease by restoring immune function. 18 Regarding mortality, the risk of death in HIV 
patients with TB is twice that of HIV patients without TB even when factors such as 
CD4+ cell count and antiretroviral therapy are taken into account. 19 In the developing 
world, the leading cause of death among HIV patients remains TB?0 
The interplay between HIV and TB is evident from the epidemiologic data. In 
one recent global survey, an estimated 9% of new TB cases were attributable to HIV co-
infection?0 This proportion was much higher in certain areas: in the WHO African 
region, 31% of new TB cases were due to HIV and in the United States, the proportion 
was 26%. Overall, 12% of the 1.8 million deaths due to TB were attributed to HIV but in 
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the African region, 39% ofTB deaths are attributable to HN. In general, TB incidence 
rates are strongly correlated with HIV prevalence rates. Looking at the issue from the 
HN perspective, of the 40 million people living with HN worldwide, about one-third of 
them are infected with TB.Z1 
Compounding the problem: the addition of MDR-TB 
Given the dynamic interplay between HN and TB, it is not surprising that the 
addition ofMDR-TB has complicated the picture. HIV and MDR-TB are a deadly 
combination: one cohort ofHIV/MDR-TB patients had more than 50% mortality within 
two months of diagnosis.22 Longer follow up times in co-infected patients have shown 
death rates of between 72-89%.23 Another study of risk factors affecting survival in 
MDR-TB patients showed that immunocompromised MDR-TB patients are nine times 
more likely to die than MDR-TB patients who are not immune compromised.24 Many of 
the published studies involving HIV, MDR-TB and non-drug resistant TB involve small 
case series from isolated outbreaks with some larger surveillance studies. The ' 
relationship then, between HIV and MDR-TB is in a larger sense not well understood. 
This is surprising, given the body of literature devoted to HIV and MDR-TB individually. 
A key question is ifHIV predisposes TB patients to progress to active MDR-TB, as 
opposed to drug susceptible TB. The consequences of this relationship are immense in 
terms of morbidity, mortality, health care policy and spending. A relationship between 
the two would imply that health care resources for TB prevention and treatment should be 
augmented in areas of high HIV prevalence and vice versa. To get a clearer picture of the 
relationship between the two, this review intends to summarize and critically appraise 
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studies which have looked at rates ofMDR-TB in patients with and without HIV 
infection. 
METHODS 
The purpose of this review is to investigate whether TB patients co-infected with 
HIV are more likely to have multi-drug resistant tuberculosis than TB patients not co-
infected with HIV. The general strategy was frrst to come up with eligibility and quality 
criteria for published literature to be included in the review. Subsequently the body of 
literature would be searched with a predetermined search strategy. 
Eligibility criteria 
The body of evidence regarding the specific relationship between HIV infection 
and MDR-TB is lacking. While there are countless articles and even journals devoted to 
tuberculosis and HIV, the intersection of the two with drug resistance is an uncommon 
topic. As this type of systematic review has not been done before and the body of 
evidence was apparently sparse, fairly lenient eligibility criteria were chosen. 
A number of study designs were deemed to be acceptable, including case series 
(including surveillance data), cross sectional studies, case control, cohort (retrospective 
or prospective) studies and clinical trials. The wide variety of acceptable study designs, 
including traditionally weaker designs such as case series and cross sectional studies, 
were deemed appropriate because information extracted from them could reasonably 
address the study question. Association, not causation, was the relationship investigated. 
Opinion pieces written by experts were not eligible for the review. Realistically, the 
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presumption was made that most of the data would come from cohort studies, 
surveillance data and case series Although in theory a clinical trial is the best design to 
minimize biases, one would be unrealistic and unethical for this study question since the 
exposure (intervention) is essentially HIV infection. 
The next grouping of eligibility criteria related to populations, definitions and 
outcomes. All patients studied must be infected with tuberculosis. It was deemed 
acceptable if this group was formed in a manner unrelated to the main question of the 
study. Sputum culture had to be a part of the study and a positive culture had to be an 
inclusion criteria for the study population for the research study to be eligible. Only with 
this diagnostic test could further testing for drug resistance patterns (the outcome) be 
assessed. A clinical diagnosis of active tuberculosis infection based on symptoms and a 
PPD skin test would be unacceptable for eligibility. 
Regarding the exposure (HIV infection), studies must have included mention of 
how HIV infection was assessed to be eligible. This could include previous mention in 
the medical record or for example, ELISA (enzyme linked immunosorbent assay) test or 
rapid HIV tests. Also for eligibility, the studies had to give some indication of an HIV 
negative population which would serve as a control for this review. It would be 
acceptable if this grouping of HIV negative TB patients was not related to the primary 
outcome of that particular study. However, somewhere in the study, whether a table or 
within the results section, there had to be a clear indication of a grouping of HIV negative 
patients along with HIV positive. 
The possibility was discussed of including studies which only contained data of 
only TB/HIV co-infection. The original thought was that outcomes from these studies 
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could be compared to cmmtry specific levels ofMDR-TB. In this sense, the country 
wide surveillance data would serve as a proxy for MDR-TB rates in HIV negative 
patients. Nevertheless, this could be problematic as HIV and MDR-TB prevalence rates 
are not distributed uniformly throughout regions and countries. The importance of 
having an exposure group and a control group within the same study furthermore 
necessitated the inclusion of an HIV negative group within the eligibility criteria. 
Clear description of outcome measurement is an important eligibility criterion. 
Studies had to describe culture and drug susceptibility testing done along with which 
anti-tuberculosis chemotherapy agents were tested. Resistance to both isoniazid and 
rifampin was needed for eligibility since MDR-TB is defmed by resistance to these. 
Therefore, a study would be deemed ineligible if it included individual resistances to the 
chemotherapeutic agents but did not include a combined resistance profile to both 
isoniazid and rifampin. The MDR-TB rates had to be presented as percentage or these 
percentages had to be readily extractable from data presented. If a study did not present 
percentages but did present an odds ratios or risk ratio for MDR-TB infection in HIV 
positive compared to HIV negative patients, this was also decided to meet eligibility 
criteria, 
Systematic reviews often restrict eligible studies by publication date. The logic 
stems from the fact that current clinical practice and methodologies might differ greatly 
from a predetermined time point. For this review, no publication dates were restricted. 
This came with the knowledge that any study which addressed HIV and MDR-TB is 
inherently time restricted. MDR-TB emerged as a threat within the past two decades and 
most of the literature regarding it has been written since 1990. 
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Tuberculosis cases occur under different circumstances: they can be epidemics 
on inpatient hospital wards or can be community based. They can be new cases or 
recurrent. These distinctions are important in classifying the type of patient and the type 
of disease. They are also key determinants of rates ofMDR-TB. In the early history of 
MDR-TB, the infection spread in hospital wards from one HIV patient to another. 
Intuitively, with a few patients spreading MDR in an HIV ward, outcome rates would 
probably be higher in HIV co-infected patients compared to HIV negative patients. The 
outbreak and patient proximity associated with it could be considered a confounding 
factor. This does not necessitate elimination from the review but is important 
information to glean from each study. The same holds true for the distinction between 
new and recurrent cases ofTB. MDR-TB is much more likely in recurrent cases because 
failed initial treatment is a risk factor for drug resistance. Hence, a study which included 
more recurrent cases than new cases would more likely have higher overall rates of 
MDR-TB. While this information would be critical for an accurate interpretation of 
study results and biases, it was not included in the eligibility criteria because of the 
possibility of eliminating too many studies. 
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Clinical trials, cohort studies 
(prospective or retrospective), case 
control, cross sectional, case series, 
surveillance data 
Study population 
I. Culture positive TB patients with 
drug susceptibility result 
2. Inclusion ofHIV infected and .. 
uninfected individuals 
Description of data I. HIV status 
collection 2. Resistance testing for isoniazid 
and rifampin 
Publication date Any 
Geographic location Any 
Quality criteria 
After eligibility criteria, a set of quality criteria to grade the internal validity of 
possible studies was needed. Traditionally, this grading system includes elements such as 
proper randomization scheme, allocation concealment, intention to treat analysis and 
proper masking (blinding). Given the wide variety of study designs and lack of 
randomized control trials, these quality criteria would be inappropriate for this review. 
We therefore opted to include all eligible studies, independent of their quality but 
assessed all included studies according to the quality criteria listed in Table 2. Many of 
the quality criteria are inherently related to the eligibility criteria. Cases of tuberculosis, 
HIV, and drug-resistant TB had to be explicitly defined with culture and diagnosis 
method. There should be no indication that resistance testing was assessed differently in 
HIV positive and HIV negative groups. 
12 
Prerequisites of sufficiently large sample sizes are oft used quality markers. For 
this review, there was no minimum sample size required for eligibility. Given the paucity 
of data on this particular clinical question, any studies which met the other criteria were 
considered important in being able to assess the relationship between HIV and MDR-TB. 
However, sample sizes were duly noted as a quality indicator. The quality criteria table 
(Table 2) notes whether each study had a sample of at least 5Q patients in both the HIV • 
positive and HN negative groups. 
Appropriate statistical measures are another useful measure of quality for this 
review. Generally studies present two percentages ofMDR-TB infection, one in HIV 
positive and patients and the other in HIV negative patients. While the sole presentation 
of these numbers is valuable, statistical testing of the differences is an important indicator 
of quality. This information was noted during the appraisal of each study. 
An assessment of baseline differences is an important quality criterion. The 
comparability of groups, in this case HIV positive and HIV negative populations, would 
be important for knowing if confounding factors (that are associated with HIV infection 
and MDR~ TB acquisition) are possibly driving a relationship between the two. Ideally, 
this assessment would be present in the studies in the form of a demographics table. 
However, any descriptive analysis in the text was also sought as an indicator of quality. 
Even if statistical adjustment is not done for the confounders, the knowledge of possible 
differences between the groups is crucial. Since the goal of this review is to investigate 
the risk ofMDR-TB attributable to HIV, the possibility that other variables are driving 
the relationship is important. Association with HIV does not imply causation. 
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Linked to the baseline characteristics is the question of whether groups selected 
are representative samples of the population at large. This would be important in 
assessing the external validity, or generalizability, of studies. In most cases then, we 
would not be able to assess how valid study results are to another population of baseline 
TB patients. This is an important issue which must be considered during the larger 
implications of the review, particularly since geography plays such an important.role in 
rates of TB and HIV. In this review, an assessment of generalizability by the study 
authors is considered a quality standard. Even if the authors note poor generalizability, 
their consideration demonstrates concern about the implications of their study. 
Masking, another traditional quality criterion, is not included in this review. The 
one stage in the clinical question for this review where masking would be appropriate is 
resistance assessment by a laboratory technician. Ideally, this person would be blinded 
to HIV status. This is generally the case since drug resistance testing is done in 
laboratories that are normally unaware of the HIV status of the patient 
TABLE 2· QUALITY CRITERIA 
• Sample size > 50 
• Statistical testing of differences 
• Description of baseline characteristics 
• External validity considered 
Search strategy 
Articles were searched using the MEDLINE/PubMed database. Other databases 
were not used due to the strictly clinical nature of the research question. The keywords 
"multi drug resistant tuberculosis" and "HIV" were used as search terms instead of the 
MeSH terms "Tuberculosis, Multidrug-Resistant" and "HIV" because considerably more 
articles come up in the broader keyword search. The search included all articles 
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published prior to April 2007. The initial search yielded 738 articles which were then 
limited to English language and human subjects studies. This led to 577 articles. The 
titles and abstracts of these articles were reviewed for subject matter related to the topic 
and broadly evaluated for eligibility criteria. Two hundred articles were selected for full 
text review. Afterwards, there were 22 articles which met the specified eligibility criteria. 
The references ofthese were hand searched for potentially relevant articles. This method 
yielded four additional studies which met the eligibility. One of the studies found was a 
meta-analysis of European studies that included seven studies in its calculation of an odds 
ratio for the outcome of interest of this systematic review. 
The group of studies ranged in publication date from 1992 to 2006. A wide 
variety of geographic areas were covered including four studies from Europe, nine from 
the United States, three from Latin America, three from Southeast Asia and seven from 
sub-Saharan Africa. Of note, no eligible studies were found that were based on data from 
Russia, former Russian republics, India or China. These areas contain a substantial 
portion of the burden of suffering of drug resistant and drug susceptible tuberculosis. 
The glaring omission of these areas from published data is highly relevant to the general 




PubMed!MEDLINE searched with 'multi drug resistant 
tuberculosis hiv' search terms, yields 738 articles 
English language and human subjects limits placed, yields 
577 potentially relevant articles 
' 
. 
Titles/abstracts reviewed, 377 out of scope of the topic and 
removed, yields 200 articles 
Reviewed text/references of 200 articles, applied 
inclusion/exclusion criteria, yields 22 articles 
26 studies used 
in review 
Added 4 studies based 
on hand search of 
references 
Critical appraisal of the studies and data extraction was done in groups defined by 
geographic areas. 
Southeast Asia 
The studies from this area include have all been published since 2000 and include 
one from Bangkok25, one from the Chiang Rai province of northern Thailand26 and one 
from Ho Chi Minh City in Vietnam27 The authors of the two much larger studies from 
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Thailand concluded that HIV patients were more likely to have MDR-TB than HIV 
negative patients. The study from Vietnam showed no association between the two, but 
the sample size, particularly for the HIV + group was miniscule. 
Punnotok et al showed a statistically significant relative risk of 11.9 (95% CI: 4.3, 
33) for MDR-TB in HIV patients compared to non-HIV patients. This strong association 
is backed by solid methodology. TB cases were well documented and HIV patients 
received both ELISA and Western blot for confirmation, limiting potential 
misclassification. A table of demographic differences shows that the two groups are 
generally comparable for TB risk factors, with the exception of smoking history and 
history of alcohol drinking. However, like many of the studies included for review, there 
is a large discrepancy between the number of patients originally recruited and those 
tested for HIV and TB drug susceptibility. There is no good indication of whether the 
patients who did not receive all tests were systematically different from those who did. 
Another possible source of bias is addressed by the authors. TB infection in HIV patients 
may reflect more recent infection, as opposed to reactivation of latent infection. Thus, 
TB drug resistance patterns in HIV patients more closely reflect those strains currently 
circulating in the community. 
Yoshiyama et al present a strong case for an association between HIV and 
primary MDR-TB in the Chiang Rai province ofThailand26 They find a statistically 
significant odds ratio of2.0 (95% Cl: l.l, 3.5) in a large sample ofHIV positive and 
negative patients. This study also provided separate results for acquired cases ofMDR-
TB due to recurrent TB infection. There was no significant relationship between 
acquired MDR-TB and HIV status (OR 1.40, 95% CI: 0.68, 2.91). This supports the 
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hypothesis that primary infections are associated with recent strains that are more likely 
to be drug resistant. In the study, HIV testing and TB drug resistance surveillance were 
done in a clear and appropriate manner. However, the primary research question was not 
to assess the difference in MDR-TB rates by HIV status; rather, they sought to fmd the 
prevalence of drug resistance in Chiang Rai and look for other associated risk factors. As 
such, there is no baseline comparison of risk factors in HIV positive and MIV negative 
patients. This raises the possibility of confounders influencing the relationship. 
Furthermore, the external validity of the findings is questionable given the lack of 
baseline characteristics. 
The third study from Southeast Asia from Quy et a! shows no statistically 
significant relationship between HIV status and MDR-TB in a group from Ho Chi Minh 
City, Vietnam?7 There was no association even after adjustment for age, sex and 
treatment history. The rate ofMDR-TB in HIV negative patients was 21.3% while it was 
0% in their sample ofHIV positive patients. However, there were only six HIV positive 
patients who had resistance testing done, compared to 188 HIV negative patients. The 
authors conceded that the study only had 20% power to detect a two-fold increase in 
MDR rate in HIV positive patients compared to negative. 
Sub-Saharan Africa 
Seven studies from sub-Saharan Africa are included in this review. They range in 
publication from 1992 to 2001. Most of the studies are from southern sub-Saharan Africa, 
including South Africa, Botswana and Mozambique. Two others are from Cote d'Ivoire 
and Tanzania. 
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Braun et al. undertook one of the first studies of antituberculosis drug resistance 
and HIV status in sub-Saharan Africa in 1992.28 This cross sectional prevalence study 
looked at rates of resistance to first and second line TB drugs by HIV status. Among the 
17 patients with HIV, 0% had MDR-TB and among the 29 patients without HIV, 3.4% 
had MDR-TB. The sample size is among the smallest of all studies in the review, 
particularly for the HIV positive group-(17 patients). While statistical testing was done 
on differences in some resistance patterns, it was not done for the specific MDR 
resistance pattern of isoniazid and rifampin resistance. The reason for this might be that 
the specific threat ofMDR might not have been as widely understood at the time of 
publication, There is little description of baseline characteristics of the HIV positive and 
negative groups, allowing little insight into possible confounders driving the relationship. 
Like most cross sectional studies, Braun et a! simply look for an association and 
seemingly find none, which is not surprising given the small sample size. 
In a much larger survey, Chum et al. studied about one-sixth of incident TB cases 
over a three year period in Tanzania in the early 1990s to look at the relationship between 
HIV and TB infection.29 The large survey is well powered to find differences in MDR-
TB rates by HIV status. They find that in new TB cases, 1.1% of co-infected patients had 
MDR-TB and 1.1% ofHIV negative patients had MDR-TB. In recurrent TB cases, 4.8% 
of co-infected had MDR-TB while 7.7% ofHIV negative patients had MDR-TB. While 
rates in new cases are clearly similar by HIV status, no statistical testing is done to 
examine the difference in new or recurrent rates. Of note, the authors do provide some 
baseline characteristics of the participants, including sex, age, urban/rural residence and 
BCG scar status. The study group also made efforts to ensure that the TB patients 
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sampled were representative of all Tanzanian TB patients by including patient from each 
of the country's districts. 
More recently, Anastasis eta!. conducted a smaller retrospective descriptive study 
ofHIV and TB drug resistance in Durban, South Africa. 30 Overall, 2.4% of 42 HIV co-
infected TB patients had MDR-TB while 11.5% of253 HIV negative TB patients had 
MDR-TB. The authors write that no association between MDR-TB and HIV is 
demonstrated; nonetheless, statistical significance is not given. Given the smaller sample 
size and the inherent biases of retrospective chart abstraction, this one is among the 
weaker of the study designs. 
A succinct letter to the editor by Post and Wood meets the review eligibility 
criteria as well.31 It describes a prospective cohort ofTB patients admitted to a hospital 
in Cape Town, South Africa. The rate ofMDR in 88 HIV positive patients is 2.9% and 
the rate is 2.6% in 107 HIV negative patients. While no statistical test is done on the 
difference, the authors conclude their data supports the body of evidence that HIV 
infection is not associated with MDR-TB. Given the brevity of the letter, there is little 
description of the cohort by HIV status even though the measurement ofHIV and TB 
drug resistance are reasonably well described. 
A national survey from Botswana by Kenyon eta!. corroborates earlier sub-
Saharan African studies.32 The survey finds no relationship between MDR-TB and HIV 
and low levels ofMDR overall. Among HIV positive patients, rates ofMDR were 0.9% 
and rates among HIV negative patients were 0.8%. The results are combined for new and 
recurrent cases. The extensive, random sampling (based on district TB case registration) 
of the survey along with baseline characteristics of all participants reassures the reader 
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that the fmdings are externally valid to Botswana. However, like many other studies, the 
survey was not specifically designed to compare rates ofMDR-TB by HIV status. 
Accordingly, there is no information given about baseline characteristics comparing HIV 
positive versus HIV negative patients. Appropriate confounders and adjusted odds ratios 
carmot be calculated. 
Murray eta!. investigate rates of drug resistant TB in South Africangoldminers.33 
Of 425 patients with sputum positive pulmonary TB, 422 had known HIV status. Among 
those with HIV, the rate ofMDR-TB was 5.3% and among those without HIV, the rate of 
MDR-TB was 6.5%. Statistical testing is not done to test the difference between these 
two rates. While the methods of this study, including HIV and resistance testing are clear, 
there are important biases to consider. The study is not specifically undertaken to study 
the difference between HIV positive and negative patients. As such, there is no baseline 
characterization looking at the differences between these two populations. It is also 
important to consider the generalizability of these findings. A population of goldminers 
might be systematically different from others, in terms of risk factors such as crowded 
living conditions or occupational lung disease. Without a thorough description of the 
baseline populations, it is difficult to assess the possibility of confounders or address 
external validity. 
The final study included from sub-Saharan African is among the strongest. Mac-
Arthur eta!. conduct a survey ofTB drug resistance and HIV in Mozambique.34 No 
statistically significant relationship is found between MDR-TB and HIV: 2.2% ofHIV 
co-infected had MDR-TB while 3.2% of non-HIV infected had MDR-TB with odds ratio 
0.7 (95% CI: 0.2, 2.2). HIV testing and sensitivity testing is done on the entire sample of 
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culture positive TB patients minimizing bias from differential loss to follow up. This 
study is one of the few to describe baseline characteristics by HIV status. While not an 
extensive list, it does show that certain factors like education and prior STis occur at 
different rates in both groups. The health facilities used are selected randomly but the 
provinces housing those facilities are not selected randomly. The authors admit that the 
provinces not selected were systematicaLly different from those selected in health care 
resources. This could bias the survey's external validity. 
Europe 
Of the four European studies included in the review, two are surveys from 
localized areas in Spain, one is a large case control study of national laboratories serving 
80% of France's public hospitals and one is a systematic review itself. 
A prospective study by Ausina et al. from Barcelona, Spain was one of the first 
studies from Europe to address MDR-TB and HIV.35 The rate of primary MDR-TB in 
HIV patients was 0.5% while the rate in HIV negative patients was 0.6%. While there is 
no significant difference in primary resistance patterns by HIV status, statistical testing is 
not specifically done for MDR-TB. There is also insufficient information given to 
calculate the relationship between acquired MDR-TB and HIV. While this study was 
undertaken to study the differences between HIV positive and negative patients, potential 
confounding factors are also not mentioned. A comparison table by HIV status only 
addresses resistance patterns. Overall, the study suggests low rates ofMDR-TB in both 
HIV positive and negative patients. 
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A large survey conducted by Schwoebel et a! in France had data on thousands of 
TB patients from the early !990's.36 They find infection with HIV as the only 
statistically significant risk factor associated with primary MDR-TB with an odds ratio of 
5.6 (95% CI: 2.6, 12.!) for HIV positive versus HIV negative. The odds ratio presented 
is adjusted but the details of the adjusted variables are not given. No statistically 
significant relationship is found between acquired MDR-TB and HIV. The main , 
strengths of the study are the large sample size (10267 HIV negative patients and 893 
HIV positive patients with primary TB) and good external validity since the network of 
laboratories used served 80% of French public hospital beds. Unfortunately, since rates 
ofMDR-TB by HIV status were not the only outcome, there is insufficient description of 
baseline characteristics and inadequate discussion of confounding factors. Nonetheless, 
the template of a large scale TB survey is useful for future studies on MDR-TB and HIV. 
The only systematic review/meta-analysis taken for this review is by Faustini et 
aL37 Its purpose is to assess risk factors for MDR-TB in Europe and contains seven 
studies with data on the specific question ofHIV and MDR-TB (one of which is the 
Schwoebel paper which constitutes about 25% of the 'weight' of the final odds ratio). 
The fact that not all the component studies are found in this larger review highlights some 
of the difficulties of systematic review. For example, not all the studies included in 
Faustini are even found in the initial broad PubMed search. While the component studies 
could be subsequently appraised, they were not because this would essentially repeat the 
work already done by Faustini. However, the Schwoebel article was included since it 
was found using the a priori search strategy. The combined data ofFaustini show a 
statistically significant odds ratio of3.52 (95% CI: 2.48, 5.0!) for MDR-TB in HIV 
23 
positive patients. The search strategy and statistical analyses are well described. Basic 
characteristics of the studies reviewed are given but a detailed description of patient 
populations, particularly among those included in the 7 studies analyzing HIV, are not 
given. Interestingly, some variables that can be considered confounders in other studies 
are used as criteria for study exclusion; these include TB cases limited to an outbreak and 
studies limited to high risk groups such as prisoneis. While the authors did not provide a 
critical appraisal of individual studies, they discussed limitations in broad terms. The 
authors admit that selection bias is a major problem given the way groups were formed. 
Also importantly, there is missing data on risk factors. Because these limitations are not 
specifically discussed for the seven studies analyzing HIV, the meta-analysis is not as 
strong. The role of publication bias, an important consideration in meta-analyses, is also 
left unaddressed. 
The most recent study from Europe was from the Castilla-Leon region of Spain. 38 
The study showed that overall rates ofMDR-TB are low in this particular region and 
suggests no relationship between MDR-TB and HIV. The rate ofMDR-TB in HIV 
patients was 0% (out of 59 sampled) and the rate was 0.1% in HIV negative patients. 
The odds ratio for MDR-TB infection in HIV patients is not significant at 0.19 [0-4.8]. 
The small sample ofHIV patients and the low levels ofMDR-TB in the region lead to the 
wide confidence interval. The patient population is not well described though attempts 
are made to make the sample representative of the area of Castilla-Leon. Nonetheless, 
these efforts are not fully described. The authors also write that independent variables 
associated with drug resistance are identified with logistic regression but these variables 
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are not described afterwards. The reader is left unsure whether the odds ratio presented 
for MDR-TB is adjusted for these variables. 
Latin America 
Campos eta!. published one of the first Latin American studies ofMDR-TB and 
HIV in 2003. This study found one ofthe.strongest associations between HIV and MDR-
TB as 43% ofHIV/TB patients had MDR-TB while only 3.9% of non-co-infected 
patients had MDR-TB. The difference is statistically significant with a large sample sizes 
in both comparison groups. The study gave a table of baseline characteristics comparing 
HIV positive and HIV negative patients which suggests certain important differences 
between groups. These include marriage status, income, exposure to TB at work, 
inpatient care and receiving ambulatory care at hospitals/health centers. Although these 
factors are not adjusted for, they at least provide an indication of possible associated 
variables which confound the relationship. One major concern is where the two groups 
were drawn from: HIV patients were recruited exclusively from hospitals whereas HIV 
negative controls were recruited from clinics. The groups might not be apt for 
comparison. Because hospitalized patients with TB are more likely to have MDR-TB 
than patients treated at community-based clinics independent of HIV infection status, this 
study is likely to overestimate the association between HIV and MDR-TB. Among other 
concerns, this would limit external validity to all HIV patients. 
A small study from Brazil by Liberato et a!. found no significant relationship 
between MDR-TB rates by HIV status.39 Of the HIV co-infected patients, 6.3% had 
MDR-TB while of the HIV negative patients, 6.6% had MDR-TB. The sample sizes 
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were small, particularly for HIV patients, for which there were only 16. Since the 
primary goal of this study was to elucidate characteristics ofHIV positive and HIV 
negative TB patients, there is a table of comparison between the two groups. Some of the 
differences between the groups include sex, IV drug use, and male homosexual relations. 
Key variables which are similar include previous TB exposure and alcohol consumption. 
Some possible confounders of the relationship such as hospitalization are not included .• 
Although the study shows no difference by HIV status, the potential effect of 
confounders would be useful to consider. Generalizability of the findings was not 
explicitly addressed. However, since patients were recruited from outpatient clinics, they. 
might be more representative ofTB patients than recruiting just from hospitals. Since 
this study was undertaken in the Northeastern region of Brazil, it would also be useful to 
compare the characteristics of the health system here with other parts of Brazil. 
The third study from Latin America is a recent one from Haiti by Joseph et al.40 
The authors find a significant association between co-infection with HIV and primary 
MDR-TB (10% ofHIV infected versus 3% ofHIV negative). The authors also find no 
significant relationship between co-infection with recurrent TB/HIV and MDR-TB. The 
sample sizes are small only for the recurrent TB cases. Regarding baseline characteristics, 
the authors write that none were associated with primary or recurrent drug resistance but 
those investigated were not listed. As such, the potential for unknown confounders 
remains. The authors even raise the possibility that transmission ofMDR-TB at 
voluntary counseling and testing centers (VCTs) could fuel the spread of the disease.· 
The authors also comment that since national rates in Haiti are unknown, assessing 
external validity is difficult. 
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North America 
One of the most important studies which brought attention to the problem of 
MDR-TB was published in 1993 by Frieden et a1 based on data from New York City.41 
There was a statistically significant difference in MDR-TB rates by HIV status: 19.5% of 
HIV patients had MDR-TB while 2% of patients with unknown HIV status did. The 
comparison of HIV patients to those with unknown, status could bias the results towards 
the null if there were by chance HIV positive individuals in the unknown group. Since 
the study gives a broad description of the emergence of drug resistant TB in New York 
City, the comparison ofMDR-TB rates by HIV status is not the primary outcome. As 
such, there is no description of baseline characteristics or discussion of confounding 
factors. Since the study included TB patients from New York City, the generalizability to 
other populations outside this area is questionable. 
Gordin eta!. investigated the relationship between MDR-TB and HIV but with 
the primary intention of comparing a New York City based population to a mixed group 
from seven other metropolitan areas.42 In New York, there was a statistically significant 
difference in MDR-TB rates by HIV status: 19.4% for HIV positive patients and 5.8% for 
HIV negative. On the other hand, outside of New York, there was no statistically 
significant difference in MDR-TB rates: 2.8% in HIV positive patients and 1.4% in HIV 
negative patients. While there was no comparison of baseline characteristics by HIV 
status, there was a comparison of New York City patients to non-New York patients. 
Possible confounders like homelessness, unemployment, alcohol use and the use of street 
drugs were different between the two groups. Because this study samples a wide variety 
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of patient populations throughout the United States, it has better external validity than 
studies limited to one area. 
A subsequent descriptive analysis by Moore et al. analyzed national data from the 
United States from 1993-1996, which included a subset of the patients used in the Gordin 
study.43 However, it is nnclear exactly how much of the data is overlapped. Moore 
showed two statistically significant differences in MDR-TB rates by HIV status, one for 
US born patients and one for foreign born patients (both groups were aged 25-44 years 
though). Among US born, rates in HIV infected were 6.4% while rates in HIV 
nninfected were 1.4%. Among foreign born, rates in HIV infected were 4.7% while rates 
in HIV uninfected were 3.0%. There is little description of the population aside from the 
resistance data; therefore, it is difficult to assess the importance of outside variables that 
could have confounded the two relationships. Because this study contains data of all TB 
patients from the United States, the study is more widely generalizable. 
The data used by Moore et al. was also later published by the CDC in a Morbidity 
and Mortality Weekly Report.44 Here the results were not split by foreign born status. 
Among all HIV patients, 6.2% had MDR-TB while in HIV negative patients, !.3% had 
MDR-TB, which was a statistically significant difference. Once again, there is no 
description of patient characteristics which could help point to confounding factors. 
Moore et al. subsequently published a limited part of the same data set (only TB 
cases from 1993-1994) and found a statistically significant result similar to the previous 
two analyses: 6% MDR-TB rates in HIV patients and 2% MDR-TB rates in HIV 
negative patients.45 In this study though, limited demographic and clinical characteristics 
were given, which suggest that the populations are not exactly comparable. HIV patients 
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were younger, more likely to be male and more likely to be born in the United States. 
Other important variables of interest like hospitalization and drug use are not listed. 
Rates of previous TB were similar. 
Localized surveillance data continued to be published with Liu et a!., who 
specifically looked at drug resistance patterns in New Jersey in the early 1990s.46 There 
was therefore some degree of overlap with the national data,published by Moore. MDR-
TB rates in HIV patients were 4.9% while they were 1.2% in HIV negative patients. The 
odds ratio for MDR-TB in HIV compared to non-HIV was statistically significant at 3.6 
(95% CI: 1.5, 8.8). Like the many other studies which looked at risk factors, Liu eta!. 
examine factors such as previous TB, homelessness, and injection drug use but do not 
stratifY by HIV status. It is difficult then to assess possible confounders. Because of the 
close proximity ofNew Jersey to New York City, the authors admit that the 
generalizability of these findings remains questionable. 
In 1998, Spellman et a!. published data from a prospective evaluation of TB 
patients in Ft. Worth, Texas.47 They found no significant relationship between MDR-TB 
rates but HIV positive patients actually had the lower one. Rates in HIV patients were 
0% while they were 4% in HIV negative patients. The difference between HIV positive 
and negative patients is a primary outcome; therefore, the authors present a table of 
baseline characteristics which highlight some major differences between the groups such 
as history of drug use and being foreign born. Notably, rates ofhomelessness and 
alcohol use are similar between the groups. Previous hospitalization is not listed. Since 
all TB cases were included from a set time period in Ft. Worth, Texas, the findings are 
generalizable to both clinic and hospital patients. 
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Soon after, Taylor et al. published a wider survey ofTB in Texas with data from 
1987 to 1996.48 Like the Spellman study, this found no significant relationship between 
HIV and MDR-TB. Rates in HIV positive patients were 1.1% and rates in HIV negative 
patients were 1.4% with a risk ratio of0.78 (95% CI: 0.50, 1.21). Demographic and 
clinical variables like history of incarceration, drug abuse, and recurrent TB are presented 
but not by HIV status. However, the authors do state that there was no nosocomial or 
prison outbreak ofMDR-TB during this time. Regardless, to assess the risk ofMDR-TB 
attributable to HIV, more specific information is needed. Given that all TB patients were 
included and there were no real eligibility criteria, the external validity is sound. 
The final study from the United States was a time series of four cross sectional 
surveys of TB in New York City, beginning in 1991 and finishing in 2003.49 The odds 
ratio for MDR-TB in HIV positive compared to negative was 7.3 (95% CI: 2.7, 20.0) in 
1991, 5.5 (95% CI: 0.96, 30.8) in 1994, 1.0 (95% CI: 0.2, 5.2) in 1997 and 0.8 (95% CI: 
0.04, 17.5) in 2003. The last two surveys show no association between HIV and MDR-
TB in New York. Baseline characteristics are presented for all TB patients. The 
characteristics do suggest changing rates of drug use, previous treatment and foreign born 
among TB patients. Unfortunately, it is not possible to assess the role of these possible 
confounders since they are not presented by HIV status. As with the other studies from a 
specific area, the findings in New York over these 4 surveys are not obviously 
generalizable because of specific variables that might be unique to the area (such as 
percentages of foreign born or drug users etc). 
30 
TABLE 3· BASIC INFORMATION AND RESULTS OF INCLUDED STUDIES 
% MDR- %MDR-
Number TB in Number TBin Authors' conclusion 
Year of ofHIV+ HIV+ of HIV- HIV- regarding risk of MDR-TB 
First author Publication Country patients patients patients patients in HIV+ patients 
SOUTHEAST ASIA 
Punnotok"" 2000 Thailand 192 5% 685 0.4% Increased risk, RR 11.9 
[95% Cl: 4.3, 33] 
Yoshiyama 2001 Thailand 
-primary MDR-TB 377 8.5% 474 4.4% Increased risk, OR 2.00 
- •· [95% Cl: 1.1, 3.5] ' 
-acquired MDR- 49 40.8% 85 32.9% No increased risk, OR 1.40 TB [95% Cl: 0.68, 2.91] 
Quy<' 2006 Vietnam 6 0% 188 21.3% No increased risk 
SUB-SAHARAN AFRICA 
Braun 1992 Cote d'lvoire 17 0% 29 3.4% No increased risk* 
Chum= 1996 Tanzania 
-primary MDR-TB 275 1.1% 816 1.1% No increased risk* 
-- acquired MDR- 21 4.8% 52 7.7% No increased risk* TB 
Anastasis 1997 South Africa 42 2.4% 253 11.5% No increased risk* 
Post 1997 South Africa 99 2.6% 115 2.9% No increased risk* 
Kenyon".: 1999 Botswana 107 0.9% 119 0.8% No increased risk 
Murray 2000 South Africa 207 5.3% 215 6.5% No increased risk* 
Mac~Arthur 2001 Mozambique 179 2.2% 530 3.2% No increased risk, OR 0.7 
[95% Cl: 0.2, 2.2] 
. 
EUROPE 
Ausina"~ 1995 Spain 184 0.5% 317 0.6% No increased risk* 
Schwoebel 1998 France 
--primary MDR-TB 893 1.2% 10267 0.2% Increased risk in primary, OR 5.6 [95% Cl: 2.6, 12.1] 
-- acquired MDR- No increased risk in 107 11.2% 2015 3.9% acquired MDR, OR 1.6 TB [95% Cl: 0.8, 3.1] 
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Faustini37 2006 Europe 2843 4.1% 49111 1.2% Increased risk, OR 3.52 
(systematic [95% Cl: 2.48, 5.01] 
review} 
Alberte- 2006 Spain 59 0% 926 0.1°/1) No increased risk, OR 0.19 
Castineiras38 [95% Cl: 0, 4.8] 
LATIN AMERICA 
Campos 2003 Peru 81 43% 965 3.9% Increased risk 
Liberato~:~ 2004 Brazil 16 6.3% 76 6.6% No increased risk 
-~~ 
" " 
Joseph 2006 Haiti 
-primary MDR-TB 115 10% 166 3% Increased risk in primary, RR 3.2 [95% Cl: 1.1, 8.9] 
- acquired MDR- 16 0% 33 30% No increased risk in TB recurrent 
UNITED STATES 
Frieden 1993 USA (NYC) 82 19.5% 145 2% Increased risk 
Gordin 1996 USA 
-- New York City 252 19.4% 69 5.8% Increased risk in NYC 
--non-NYC 179 2.8% 473 1.4% No increased risk in non-NYC 
Moore4~ 1997 USA 
-USA born 6.4% 1.4% Increased risk 
6442 5855 
(total) (total) 
-- foreign born 4.7% 3.0% Increased risk 
Liu 1998 USA (NJ) 556 4.9% 413 1.2% Increased risk 
Spe!lman4 ' 1998 USA (TX) 646 0% 55 4% No increased risk 
CDCMMWR 1998 USA 5112 6.2% 3754 1.3% Increased risk 
Moore 1999 USA 6833 6% 42828 2% Increased risk 
Taylor 1999 USA (TX) 2221 1.1% -- 1.4% No increased risk, RR 0.78 
[95% Cl: 0.50, 1.21] 
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Munsiff'9 2006 USA (NYC) -- -- - --- No increased risk in last 
two surveys, ORs from 4 
years: 1991 OR: 7.3 [95% 
Cl: 2.7, 20.0], 1993 OR: 5.5 
[95% Cl: 0.96, 30.8], 1997 
OR: 1.0 [95% Cl: 0.2, 5.2], 
2003 OR: 0.8 [95% Cl: 
0.04, 17.5] 
*Signifies no statistical testing done to test the difference 
TABLE 4· QUALITY CRITERIA 
Statistical Baseline External 
Sample testing of characteristics validity 
AUTHOR size> 50 differences described considered 
SOUTHEAST ASIA 
Punnotok'"" 
./ ./ ./ ./ 
Yoshiyama 
--primary MDR-TB 
./ ./ X X 
-acquired MDR- X ./ X X TB 
Quy"' X ./ X ./ 
SUB-SAHARAN AFRICA 
Braun'"' X X X X 
Chum 
-primary MDR-TB 
./ X ./ ./ 
- acquired MDR- X X ./ ./ TB 
Anastas is X X X ./ 
Post 
./ X X X 
Kenyon~~ 
./ ./ X ./ 
Murray"" 
./ X X X 
Mac-Arthur 
./ ./ ./ ./ 
EUROPE 
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Ausfna35 ,/ X X X 
Schwoebel36 
-primary MDR-TB ,/ ,/ X ,/ 
~- acquired MDR ,/ ,/ X ,/ 
Faustinf31 ,/ ,/ X ,/ 
(systematic review) 




Campos:.o ,/ ,/ ,/ ,/ 
Liberato X ,/ ,/ ,/ 
Joseph 
--primary MDR-TB ,/ ,/ X ,/ 
-acquired MDR~ X TB 
,/ X ,/ 
UNITED STATES 
Frieden ,/ ,/ X X 
Gordin 
~-New York City ,/ ,/ X ,/ 
-non-NYC ,/ ,/ X ,/ 
Moore 
--US born ,/ ,/ X ,/ 
--foreign born X ,/ X ,/ 
Liu4 , ,/ ,/ X X 
Spellman ,/ ,/ ,/ ,/ 
CDCMMWR ,/ ,/ X ,/ 
Moore4 :. ,/ ,/ ,/ ,/ 
Taylor ---. ,/ X ,/ 
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Munsiff9 X X 
*signifies inability to assess 
DISCUSSION 
The twenty-six studies reviewed in this article come from different areas around 
the world and different time periods. Some are based on large nation-wide surveys while 
others are smaller studies and include just a few TB patients with and without HIV. The 
results themselves are quite disparate with some showing a strong relationship between 
HIV and MDR-TB and others showing no effect. To understand the implications of the 
synthesis in this review article, it is necessary to consider the possible biological 
mechanism of a link between HIV and TB drug resistance. 
Possibilities for a causal/ink 
Dye considers five possible mechanisms linking drug resistant TB to HIV 51 One 
·is "functional monotherapy". The argument is that HIV patients are more likely to be 
subjected to monotherapy, a significant risk factor for drug resistance, than non-HIV 
patients. This could occur if reduced immune function allows M tuberculosis to 
continue replication even after the initial2 month intensive treatment period (four drugs) 
in HIV patients. Thus, HIV patients would be more likely to have reproducing bacteria 
that are only treated by rifampin or isoniazid during the continuation phase ofTB 
treatment. Another cause of functional monotherapy could be due to drug malabsorption 
in HIV patients. Malabsorption of rifampin and ethambutol in HIV patients has been 
shown to lead to treatment failure 5 2 
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A second mechanism is that drug resistant strains of TB are less virulent and 
would preferentially lead to disease progression in immune compromised patients who 
cannot fight off the bacteria as easily. Data supporting this hypothesis comes from 
laboratory studies and some animal data but has not been shown in humans. A third 
possibility is that MDR-TB among HIV patients could actually be reflective of time of 
infection. Non-HIV patients who develop TB might be rea~tivating a latent infection,. 
from decades ago, whereas HIV patients who develop TB might be reactivating a latent 
infection acquired much more recently. With the increasing prevalence of drug 
resistance globally7, a higher percentage of recent infections are likely to be drug resistant 
compared to infections that occurred in the more distant past. 
A fourth mechanism linking MDR-TB to HIV involves bacterial burden. HN 
patients might harbor greater numbers of M tuberculosis than non-HIV patients because 
of immunosuppression and the inability to fight off infection. This could mean that a 
prolonged treatment course would be necessary in HIV patients to achieve the same 
levels of bacterial burden in non-immune compromised patients. This pathway could 
then be tied to functional monotherapy since more HIV patients would possibly enter the 
continuation phase of TB therapy with uncontrolled levels of bacteria. Having more 
bacteria could also make the population of M tuberculosis in HIV patients more 
genetically diverse and thus inherently more susceptible to drug resistance. 
The final mechanism on which Dye focuses is shared risk factors for HIV and 
drug resistant TB strains. These shared risk factors can essentially be considered 
confounders of the relationship between MDR-TB and HIV. Confounding occurs when 
the exposure effect is mixed with the effect of another variable, which causes bias. 53 Dye 
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suggests injection drug use and hospitalization as two possible confounders. Injection 
drug use is a risk factor for HIV infection but also for tuberculosis and MDR-TB. 
Hospitalization is a confounder because it is associated with HIV infection and also 
associated with conditions needed for the spread ofMDR-TB such as close contact. 
Unrecognized MDR-TB infection in a hospital could spread quickly among HIV patients 
because of immune suppression. By the same token,outbreaks ofMDR-TB in,the 
community are more likely to appear in HN patients because they are the most 
susceptible.54 Other possible shared risk factors include imprisonment, education level 
and other measures of socioeconomic status, unemployment and alcohol use. Of note, it 
might be useful to consider time of TB infection, which is labeled in the causal pathway, 
as a confounding variable as well. Time since infection is associated with resistance 
patterns but it also might be associated with HIV infection as well. 
The difference between the causal pathway from HIV to MDR-TB and 
confounding factors is critical. The goal of this review is to understand if HIV on its own 
confers a specific attributable risk for MDR-TB, measurable with odds ratios or risk 
differences. These specific risks are difficult to glean from the published literature 
because of the important effects of confounding factors. Ideally, adjusted risk ratios 
would be presented which take into account factors like hospitalization, socioeconomic 
status or imprisonment. Unfortunately, given the current available data, these estimates 
cannot yet be calculated. 
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What can we learn from the published studies? 
FIGURE2 
Except for the studies from Africa, where the majority of studies fail to 
demonstrate an association between HIV and MDR-TB, the results from studies 
performed in other regions of the world produced conflicting results. 
The initial history ofMDR-TB in the early 1990s seemed to show strong evidence 
of a link with HIV. In a seminal paper, Frieden eta! show that in some of the first 
documented outbreaks of nosocomial MDR-TB in New York City, HIV was a significant 
risk factor.41 Speculation for the association stemmed from the causal possibilities listed 
previously. The large CDC survey as well as national data published by Moore eta! 
appeared to confirm the initial findings from New York City. However, at the same time, 
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other smaller studies found no relationship. Perhaps one of the most illuminating studies 
was that ofMunsiffet a! which calculated four time series odds ratios for MDR-TB 
infection by HIV status based on surveillance data from four surveys over twelve years in 
New York City. The lack of association between HIV status and MDR-TB in the most 
recent surveys suggests a time trend that is difficult to glean from a cursory look at the 
results of other studies from the United States. One conclusion of this study could be that , 
the relationship between MDR-TB and HIV can change over time. However, another 
possibility is that the confounding variables are the ones that changed over time and the 
risk attributable to HIV remained the same. This is certainly a possibility in New York 
where variables like hospitalization, proportion of foreign born and outbreak control 
could have changed. 
The studies from Europe show no clear trend. Two of the smaller studies, both 
from Spain, show no relationship between MDR-TB and HIV. However, given the small 
numbers ofMDR-TB cases in both of these studies, neither provides convincing data. 
F austini et a! provide a meta-analysis of European studies, which includes the 
Schowoebel study from France. The combined large sample (n=2727 for HIV positive 
and n=48571 for HIV negative) of the meta-analysis gives an odds ratio of3.52 (95% CI: 
2.48, 5.01) for MDR-TB by HIV status but the authors admit that the selection ofHIV 
infected patients may have been biased. Regardless, the authors contend that their results 
suggest that HIV infection favors the transmission ofMDR-TB compared to drug 
sensitive TB in Europe in the late 1990s and early 2000s. As the estimate was not 
adjusted for potential confounders, it remains uncertain if HIV is the driver of the 
association or whether the association is due to the presence of confounding variables. 
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Studies from Latin America also produced contrasting results. The studies are 
notable for being among the few that consider baseline characteristics as potential 
confounders of the relationship between HIV and MDR-TB. While neither offers 
statistical adjustments, Campos in particular suggests that income, workplace exposure to 
TB, inpatient care and receiving ambulatory care may be confounders of the association 
between HIV and MDR-TB. 
Of the three studies from Southeast Asia, two Thai studies found a statistically 
significant relationship between HIV and MDR-TB whereas the study from Vietnam 
found no significant relationship. Yoshiyama encourages the reader to apply the lesson 
from Munsiff et a!, which is that local factors are important in determining the 
relationship between HIV and MDR-TB. Similar to the US and Europe, Thailand 
introduced rifampin before the emergence ofHIV.Z6 Once HIV did emerge, MDR-TB 
strains were probably already circulating and the stage was set for an upsurge in MDR-
TB cases, especially among HIV patients who progress quickly from infection to disease. 
Nonetheless, the contribution of unaccounted for confounders in these studies clouds the 
association between MDR-TB and HIV. 
One of the most important fronts for TB/HIV co-infection is sub-Saharan Africa. 
While the seven studies from that region included in this review may have had limitations, 
none found a relationship between HIV and MDR-TB. The studies came from a variety 
oflocales and ranged from the early 1992 to 2001. Taken as a whole, they suggest that 
during this time period in sub-Saharan Africa, it seems likely that there was no 
association between drng resistant TB and HIV. The contrast with other regions in the 
world could be related to the timing of introduction of rifampin. The relatively high cost 
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of rifampin led to delayed introduction of this drug into sub-Saharan African. 
Consequently, MDR-TB may not have had the opportunity to take hold in sub-Saharan 
Africa prior to the time when HIV began its devastating conquest of the continent. HIV 
uncovered the untold amount oflatent TB infections, but these had yet to acquire drug 
. resistance. It is important to note that the most recent study from Africa was published in 
2001. Most recently, outbreaks ofXDR, or extensively drug resistant tuberculosis 
(defined as resistance to isoniazid, rifampin and at least three classes of second-line 
drugs), have brought frightening implications for the continent. One study from South 
Africa argued that the prevalence ofMDR is higher than earlier estimated and that XDR 
is being disproportionately transmitted to HIV infected patients. 55 The changing 
epidemiology ofMDR and XDR in South Africa might indicate an altering of the 
previous balance between MDR-TB and HIV. However, the body of literature on XDR-
TB is still small. 
Assessing publication bias 
When considering the results and implications of a systematic review, it is 
imperative to judge the contribution of publication bias. A review is only as strong as its 
component studies but its strength is also determined by what information is not included. 
Traditionally this form of bias refers to the publication of only studies that show a 
statistically significant association or effect. Although this review is not a meta-analysis 
and there is no funnel plot to assess publication bias, there are some reassurances against 
this traditional form of publication bias. First of all, a number of the studies in this 
review actually show no significant relationship between MDR-TB and HIV. Secondly, 
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the relationship between the two was often not the primary research question in many 
studies. Some were surveys to fmd the proportion of TB cases which were drug resistant 
in the whole population and others were intended to explore a number of risk factors for 
MDR-TB. Accordingly, the relationship between HIV and MDR-TB was often a 
secondary outcome and was not subject to the same publication debate as primary 
outcomes. 
Another consideration is the omission of certain countries from the published 
literature. For this review, the argument can be made that if the relationship between 
HIV and MDR-TB is causal, it would not matter where the component studies are drawn 
from. The key would be to adjust for potential confounders. However, this has not been 
readily done in the published literature. It will be important to collect data from areas 
where the burden ofMDR-TB is disproportionate, like Russia, Eastern Europe, India and 
China. While not necessarily answering the question of the attributable risk of HIV for 
MDR-TB, data from these areas would give a better idea of the current association 
between the two. 
Do we need a meta-analysis? 
The data extracted from the individual studies and presented in this review is 
amenable for pooling into one risk ratio. A meta-analysis would give a clear, qualitative 
relationship between MDR-TB and HIV. However, the presentation of one ratio should 
be considered carefully. 
The major reason not to pool the data is the poorer methodologic quality of many' 
of the component studies. To answer the question of the specific risk associated with 
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HIV and MDR-TB, calculations must be adjusted for associated variables which can 
confound the relationship. Most studies do not give baseline characteristics of HIV 
positive or HIV negative patients, do not adequately consider confounding factors and 
not a single study estimated a measure of association between HIV and MDR-TB 
adjusted for confounders. Meta-analysis would thus combine studies that were subject to 
various levels of confounding. 
Implications for practice and new research 
Given that there are no uniform results from the review, implications for clinical 
and public health practice are limited. There is no denying that HIV and tuberculosis are 
intimately linked. Health care providers should always consider tuberculosis as a cause 
of opportunistic infection in HIV patients. On the other hand, providers should consider 
HIV as a cause of reemergence of latent TB infection or a predisposal factor in newly 
acquired TB infection. As of yet, there does not seem to be the need for global caution 
for a higher likelihood ofMDR-TB among people living with HIV. Caution for MDR-
TB in the co-infected may not be a priority in the United States or sub-Saharan Africa 
currently but it may be in Southeast Asia or Europe. Nonetheless, constant vigilance will 
be necessary. The ties between HIV and MDR-TB can change as evidenced by time 
series surveys in the United States and possibly by the rising epidemic ofXDR-TB in 
sub-Saharan Africa. Steady surveillance ofMDR-TB among HIV positive and negative 
people should thus be an essential part in allocating health care resources effectively to 
combat TB and HIV. 
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In terms of public health research, this review demonstrates clear needs. More 
complete surveys on TB/HIV co-infection are needed throughout the world. These 
· surveys and subsequent publications should be undertaken with sound methodology, 
including attention to statistical tests, sample sizes, baseline characteristics and potential 
confounders. As noted, rates ofMDR-TB might vary between primary and acquired 
cases due to more resistant strains circulating at different times. To investigate this, 
future research should clearly delineate patients as either primary or acquired cases of 
MDR-TB and analyze rates in the two groups. 
The public health and medical community should not have to rely on small, 
isolated surveys for two of the largest problems in public health worldwide. The 
relationship between HIV and drug resistant TB also needs to be established in certain 
crucial areas like Russia, India and China. A final implication is that surveillance 
research of HIV and TB should be intrinsically tied together. The infrastructure for HIV 
surveillance could be hitched onto well established TB surveillance programs and vice 
versa. A united front will help combat what is becoming one massive problem of co-
infection, which is turning out to be greater than the sum of its two components. 
Furthermore, this will allow a much better appraisal of the future ofMDR-TB. 
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